Pallasch, Christian P | Heidenreich, Axel - assoc. RG 15
Exploiting tumor heterogeneity and tumor microenvironment interactions in Testicular Germ Cell Tumors (TGCT) impacting metastasis and therapy response
Prof. Dr. Christian P Pallasch
Department I of Internal Medicine
CMMC - PI - assoc. RG 15
show more…
Department I of Internal Medicine
Joseph-Stelzmannstr. 26
50937 Cologne
Prof. Dr. Dr. Axel Heidenreich
Department of Urology and Uro-Oncology
CMMC - Co-PI - assoc. RG 15
show more…
Department of Urology and Uro-Oncology
Kerpener Str. 62
50937 Cologne
Introduction
Laboratory for microenvironment and therapy of malignant lymphomas
The so-called tumor microenvironment represents the surrounding tissue of cancer cells and offers malignant tumor cells a complex environment with diverse functional relationships and interactions. In addition to the malignant tumor cells, infiltrating cells of the immune system are of great importance here. In particular, macrophages can play a role in promoting tumor growth. Through synergistic combination therapy in the tumor microenvironment, however, it is possible to reprogram macrophages into tumor-ablative effector cells (Pallasch et al. CELL 2014). Our research group focuses on the mechanisms of therapy resistance development caused by the tumor microenvironment. The mechanisms of the release of inflammatory messengers and the function of macrophages in tumor tissue after chemotherapy play a central role here. These are being further developed to develop new synergistic therapy combinations in cell culture and mouse models to enable their application in clinical trials.
Lab Website
For information about Prof. Pallasch's and Prof. Heidenreich's research and work, please visit the following pages: Research Pallsch or Urology University Hospital Cologne
Affiliations - Christian P Pallasch
Publications generated during 1/2023-12/2025 with CMMC affiliation
2024
- Beielstein AC, Izquierdo E, Blakemore S, Nickel N, Michalik M, Chawan S, Brinker R, Bartel HH, Vorholt D, Albert L, Nolte JL, Linke R, Costa Picossi CR, Sáiz J, Picard F, Florin A, Meinel J, Büttner R, Diefenhardt P, Brähler S, Villaseñor A, Winkels H, Hallek M, Krüger M, Barbas C, Pallasch CP. Macrophages are activated toward phagocytic lymphoma cell clearance by pentose phosphate pathway inhibition. Cell Rep Med. 2024 Dec 17;5(12):101830. doi: 10.1016/j.xcrm.2024.101830. Epub 2024 Nov 26. PMID: 39603243; PMCID: PMC11722127.
2023
- Hassenruck F, Farina-Morillas M, Neumann L, Landini F, Blakemore SJ, Rabipour M, Alvarez-Idaboy JR, Pallasch CP, Hallek M, Rebollido-Rios R, and Krause G (2023). Functional impact and molecular binding modes of drugs that target the PI3K isoform p110delta. Commun Biol 6, 603. doi:10.1038/s42003-023-04921-z.
- Stachelscheid J, Jiang Q, Aszyk C, Warner K, Bley N, Muller T, Vydzhak O, Symeonidis K, Crispatzu G, Mayer P, Blakemore SJ, Goehring G, Newrzela S, Hippler S, Robrecht S, Kreuzer KA, Pallasch C, Kruger M, Lechner A, Fischer K, Stilgenbauer S, Beutner D, Hallek M, Auguin D, Huttelmaier S, Bloehdorn J, Vasyutina E, and Herling M (2023). The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL. Blood 141, 1425-1441. doi:10.1182/blood.2022015494.